Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Mid-cap Health Care company Exelixis has logged a -1.2% change today on a trading volume of 1,601,263. The average volume for ...

SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.

Brookline Capital Markets analysts initiated coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and a $40 price target, ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer.

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...

Brookline Capital Markets analysts initiated coverage of Exelixis (NASDAQ:EXEL) with a Buy rating, highlighting the biotech ...